FDA 批准了第一种口服药丸 Ekterly，用于快速缓解遗传性血管性水肿发作。 FDA approves first oral pill, Ekterly, for rapid relief of hereditary angioedema attacks.

美国食品和药物管理局批准了Ekterly (sebetralstat),这是首款口服治疗12岁及以上患者遗传性血管发作 (HAE) 的需求治疗. The FDA has approved Ekterly (sebetralstat), the first oral on-demand treatment for hereditary angioedema (HAE) attacks in patients aged 12 and older. HAE是一种罕见的、威胁生命的基因障碍,导致严重的肿胀。 HAE is a rare, life-threatening genetic disorder causing severe swelling. 由KalVista制药公司开发的Ekterly为现有注射治疗提供了方便的替代药片。 Ekterly, developed by KalVista Pharmaceuticals, offers a convenient pill alternative to existing injectable treatments. 临床试验表明,它提供了迅速的症状缓解,可以在24小时内解决攻击问题。 Clinical trials showed it provided rapid symptom relief and could resolve attacks within 24 hours. 批准的目的是使病人更容易获得和方便治疗。 The approval aims to make treatment more accessible and convenient for patients.